Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
Trends Immunol
; 40(12): 1078-1081, 2019 12.
Article
em En
| MEDLINE
| ID: mdl-31732285
ABSTRACT
The promise of natural killer (NK) cells as effectors in cancer cellular therapy is limited by their expression of dominant inhibitory receptors for human leukocyte antigen (HLA) class I. Here, we discuss how chimeric antigen receptors (CARs) engineered to override inhibitory signaling might boost NK cell antitumor responses, independently of blockade of NK cell inhibitory receptors.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article